OakChart

Jade Biosciences Inc

JBIOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

16.54+0.14 (0.85%)
2026-11-12 05:51 CET
Market cap
1,051.90 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-136.45 USD m
Free cash flow, TTM
-123.57 USD m
EPS diluted, TTM
-2.61
P/E
-
Compare

Price

JBIO against its 20, 50 and 200-day averages
2050200miss
15.0020.0025.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JBIOclose 16.5420-day 14.7050-day 15.51200-day 18.2216.54

40.9% under the 52-week high of 28.00 on 27 Apr 2026. 52-week low 8.95 on 11 Nov 2025. Last 15 sessions, 26.6% high to low

Volume 0.75× normal · the line is the 50-bar volume average

Profile

JBIO
52-week range, 40% of the way up
8.9528.00

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

IndexRUT
Employees55
IPOJun 30, 2021
Beta1.63
ATR, 14d0.98
Rel volume0.75
Short float19.04%
Insider own14.30%
Inst own107.54%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.05B
Enterprise Value591.33M
Income-136.45M
Sales0.00M
Book/sh6.92
Cash/sh7.25
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees55
IPOJun 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.39
P/C2.28
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.93
Current Ratio14.93
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.61
EPS next Y-2.92
EPS next Q-0.73
EPS this Y7.45%
EPS next Y0.97%
EPS next 5Y3.74%
EPS past 3/5Y61.94% 21.92%
Sales past 3/5Y- -
EPS Y/Y TTM91.41%
Sales Y/Y TTM-
EPS Q/Q33.03%
Sales Q/Q-
EarningsAug 10 BMO
EPS/Sales Surpr.-19.42% -

Ownership

Insider Own14.30%
Insider Trans0.00%
Inst Own107.54%
Inst Trans34.57%
ROA-44.03%
ROE-47.78%
ROIC-34.78%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2012.54%
SMA506.66%
SMA200-9.23%
Trades-

Technical

Shs Outstand63.56M
Shs Float54.50M
Short Float19.04%
Short Ratio11.53
Short Interest10.37M
52W High28.00 -40.93%
52W Low8.95 84.80%
Volatility8.52% 6.31%
ATR (14)0.98
RSI (14)62.72
Beta1.63
Rel Volume0.75
Avg Volume900.00K
Volume678,986

Performance

Perf Week9.97%
Perf Month23.25%
Perf Quarter-30.53%
Perf Half Y-34.02%
Perf YTD7.19%
Perf Year68.78%
Perf 3Y-60.18%
Perf 5Y-74.36%
Perf 10Y-
Recom1.00
Target Price49.89
Prev Close16.40
Price16.54
Change %0.85%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 15, 2026InitiatedUUBSBuy$45+172.1%
Jan 07, 2026InitiatedHH.C. WainwrightBuy$25+51.1%
Oct 09, 2025InitiatedBBTIG ResearchBuy$28+69.3%
Jul 14, 2025InitiatedJJefferiesBuy$16-3.3%
Jun 16, 2025UpgradeGGuggenheimNeutral → Buy$14-15.4%
May 07, 2025InitiatedWWedbushOutperform$17+2.8%
May 05, 2025InitiatedSStifelBuy$19+14.9%
May 02, 2025InitiatedTTD CowenBuy$10-39.5%
Jun 18, 2024DowngradeWWells FargoOverweight → Equal Weight$35 → $2-87.9%
Jun 18, 2024DowngradeTTD CowenBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
VERAVera Therapeutics Inc2.20B
CLYMClimb Bio Inc719.55M
TVTXTravere Therapeutics Inc5.00B
ZBIOZenas Biopharma Inc1.95B
DNTHDianthus Therapeutics Inc5.03B
OMEROmeros Corp1.31B
ANABAnaptysBio Inc1.46B
AUPHAurinia Pharmaceuticals Inc2.17B
VRDNViridian Therapeutics Inc3.55B
IMVTImmunovant Inc7.67B

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FFSMFidelity Fundamental Small-Mid Cap ETFAUM: 1.55B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
  • Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 (GlobeNewswire)
  • Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-ß Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 (GlobeNewswire)
  • Jade Biosciences to Participate in Upcoming Conferences (GlobeNewswire)
  • Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor (FinanceWire)
  • The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush (FinanceWire)
  • Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors (GlobeNewswire)
  • Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.57%
  • Jade Biosciences Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
  • Jade Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
  • Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy (GlobeNewswire) -11.64%
  • Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy (GlobeNewswire)
  • Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-10-0.760-0.636-0.7850.000.0010
2026Q12026-05-07-0.570-0.483-0.5730.000.008
2025Q42026-03-06-0.451-0.482-0.6480.000.008
2025Q32025-11-13-0.480-0.671-0.6360.000.006
2025Q22025-08-13-0.860-0.433-1.1300.000.004
2025Q12025-05-14-12.100-6.025-3.0410.000.004
2024Q42025-03-26-6.650-6.573-6.5570.000.001
2024Q32024-11-11-19.600-16.363-19.6890.000.003
2024Q22024-08-12-30.100-28.784-30.1550.000.005
2024Q12024-05-13-29.089-26.761-29.1950.000.006
2023Q42024-03-25-25.900-23.762-25.7970.000.006
2023Q32023-11-13-24.850-24.245-24.7720.000.005
2023Q22023-08-14-26.600-24.360-26.4590.000.005
2023Q12023-05-15-23.450-20.997-23.3350.000.005
2022Q42023-03-29-21.350-21.095-21.3630.000.006
2022Q32022-11-14-19.600-17.444-19.4470.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-65.450-56.420-32.9560.000.00
2022FY-73.500-73.381-73.6710.000.00
2023FY-100.45-97.563-100.380.000.00
2024FY-71.498-85.264-85.2620.000.00
2025FY-3.190-2.880-3.1900.000.00
2026FY--2.952--0.00
2027FY--2.924--0.00
2028FY--2.845--0.00
2029FY--2.776--0.00
2030FY--2.028--131.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-105000.000.000.00
2026Q3S2026-06-285000.000.000.00
2026Q3S2026-05-086000.000.000.00
2026Q3S2026-03-096000.000.000.00
2026Q3S2026-03-065000.000.000.00
2026Q3S2026-01-065000.000.000.00
2026Q3S2025-11-214000.000.000.00
2026Q3S2025-11-143000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00

Estimate history

EPS, annual-4.775-14-32.956-73.671-100.383-85.262-4.063-2.6138
Period2019202020212022202320242025TTM
EPS, quarterly-30.155-19.689-6.557-3.041-1.13-0.636-0.648-0.573-0.757
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6970.6970.6970.7060.7930.82849.31663.556
Period2019202020212022202320242025MRQ
Shares, quarterly0.8240.8250.8280.82832.62732.62749.31649.34663.556
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.030.280.100.070.010.000.00
Gross Profit-0.04-0.03-0.28-0.10-0.07-0.01-0.000.00
Selling, General and Administrative Excl. Other164.70113.5274.3181.3153.1723.018.893.33
Research and Development136.6793.1253.1964.2238.6214.997.943.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-164.74-113.54-74.60-81.41-53.24-23.02-8.89-3.33
Interest Expense0.000.000.000.000.000.000.07-
Unusual Expense0.0021.580.000.000.000.000.640.00
Net Income Before Taxes-153.15-127.35-69.57-75.47-51.49-22.96-9.61-3.33
Income Taxes0.090.060.060.060.030.000.000.00
Consolidated Net Income-153.24-127.41-69.63-75.52-51.51-22.96-9.61-3.33
Net Income From Continuing Operations-153.24-127.41-69.63-75.52-51.51-22.96-9.61-3.33
Net Income-136.45-127.41-69.63-75.52-51.51-22.98-9.76-3.33
EPS (Recurring)-2.23-3.58-85.26-100.38-73.67-32.96-13.35-4.77
EPS (Basic, Before Extraordinaries)-2.61-4.06-85.26-100.38-73.67-32.96-14.00-4.77
EPS (Diluted)-2.61-4.06-85.26-100.38-73.67-32.96-14.00-4.77
EBITDA-164.70-113.52-74.31-81.31-53.17-23.01-8.89-3.33
Non-Operating Income (Expense)11.597.775.025.941.750.06-0.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense28.3215.818.949.414.331.490.060.00
Shares Outstanding63.5649.320.830.790.710.700.700.70
Market Capitalization1,051.901,051.9076.81625.79718.04287.80273.15-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.000.000.010.22
Gross Profit-0.01-0.01-0.01-0.01-0.00-0.00-0.01-0.22
Selling, General and Administrative Excl. Other58.9143.4434.9727.3927.783.386.3917.19
Research and Development50.0636.0528.5422.0122.550.001.5310.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-58.92-43.45-34.98-27.40-27.78-3.39-6.40-17.41
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.006.180.000.000.00
Net Income Before Taxes-55.75-40.35-31.87-25.18-32.13-2.52-5.38-16.24
Income Taxes0.010.020.060.000.000.000.060.00
Consolidated Net Income-55.77-40.37-31.93-25.18-32.13-2.52-5.43-16.24
Net Income From Continuing Operations-55.77-40.37-31.93-25.18-32.13-2.52-5.43-16.24
Net Income-46.21-33.13-31.93-25.18-32.13-2.52-5.43-16.24
EPS (Recurring)-0.76-0.57-0.65-0.64-0.98-3.04-6.56-19.69
EPS (Basic, Before Extraordinaries)-0.76-0.57-0.65-0.64-1.13-3.04-6.56-19.69
EPS (Diluted)-0.76-0.57-0.65-0.64-1.13-3.04-6.56-19.69
EBITDA-58.91-43.44-34.97-27.39-27.78-3.38-6.39-17.19
Non-Operating Income (Expense)3.173.093.102.231.830.871.031.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.755.857.424.293.901.190.982.00
Shares Outstanding63.5649.3549.3232.6332.630.830.830.82
Market Capitalization1,051.90692.89709.84281.57322.0472.7576.8160.33

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments336.1678.62122.44129.22167.384.573.51
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets12.661.491.792.286.960.100.00
Total Current Assets348.8280.12124.23131.50174.334.683.51
Net Property, Plant & Equipment0.900.210.901.250.730.040.00
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets-0.00---0.000.00
Other Assets0.070.002.282.560.300.000.00
Total Assets349.7880.33127.42135.30175.364.713.51
Short Term Debt Incl. Current Port. of LT Debt0.000.420.420.390.190.000.00
Accounts Payable2.150.222.402.581.210.620.54
Other Current Liabilities14.393.1914.824.821.151.160.12
Total Current Liabilities16.543.8317.647.782.551.770.66
Long Term Debt0.720.000.260.700.380.002.50
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.070.070.070.010.000.00
Total Liabilities17.263.9017.968.562.941.773.16
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0016.294.00
Common Equity332.5276.43109.46126.74172.42-13.34-3.64
Total Shareholders Equity332.5276.43109.46126.74172.422.940.36
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity332.5276.43109.46126.74172.422.940.36
Total Liabilities & Stockholders Equity349.7880.33127.42135.30175.364.713.51
Book Value Per Share6.7492.30137.99179.43247.22-19.13-5.22
Tangible Book Value Per Share6.7492.30137.99179.43247.22-19.13-5.22
Full-Time Employees5530514316--
Price to Book Ratio2.391.004.985.161.671.52-
Return on Assets-59.24-67.03-57.49-33.16-25.50-233.59-
Return on Equity-62.31-74.91-63.95-34.44-26.19-582.84-
Return on Invested Capital-38.23-91.10-68.84-40.42-13.29-326.79-116.56
Quick Ratio21.0920.937.0416.9068.372.645.35
Current Ratio21.0920.937.0416.9068.372.645.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-153.24-127.41-69.63-75.52-51.51-22.96-9.61-3.33
Depreciation0.040.030.280.100.070.010.000.00
Other Funds (Non Cash)33.1340.899.328.854.572.060.780.00
Funds from Operations-120.07-86.49-60.03-66.58-46.88-20.89-8.83-3.33
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.44-8.20-11.179.807.75-6.510.970.55
Cash from Operating Activities-123.51-94.69-71.20-56.78-39.12-27.40-7.86-2.78
Capital Expenditures-0.06-0.200.00-0.14-0.20-0.180.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-352.88-246.7856.0312.027.12-113.250.000.00
Purchase of Investments-477.42-261.19-19.68-123.98-147.62-113.250.000.00
Sale Or Maturity of Investments124.5314.4175.71136.00154.740.000.000.00
Other Uses-0.03-0.030.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-352.97-247.0156.0311.886.93-113.430.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock171.74360.6125.4346.000.40190.466.420.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock171.74360.6125.4346.000.40190.466.420.00
Proceedsfrom Stock Options171.41171.4123.9445.01-0.22190.466.410.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.002.502.50
Change in Long Term Debt0.000.000.000.000.000.002.502.50
Issuance of Long Term Debt0.000.000.000.000.000.002.502.50
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow191.150.160.000.000.000.000.000.00
Other Financing Activities Uses-0.840.000.000.000.000.000.000.00
Cash from Financing Activities362.89360.7725.4346.000.40190.468.922.50
Exchange Rate Effect--0.02------
Net Change in Cash-113.6919.0510.261.09-31.8049.621.06-0.28
Free Cash Flow-123.57-94.89-71.20-56.92-39.32-27.58-7.86-2.78
Preferred Dividends (Cash Flow)--0.000.000.00--0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments461.20311.30336.16198.91220.9476.21
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets10.057.2212.662.462.041.16
Total Current Assets471.25318.52348.82201.36222.9877.37
Net Property, Plant & Equipment0.790.850.900.920.920.16
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets-----0.00
Other Assets0.070.070.070.170.060.00
Total Assets472.11319.43349.78202.45223.9777.53
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.31
Accounts Payable6.583.982.151.357.590.07
Other Current Liabilities24.9918.3114.3921.0114.032.04
Total Current Liabilities31.5722.2916.5422.3621.622.42
Long Term Debt0.630.680.720.750.790.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.07
Total Liabilities32.2022.9717.2623.1022.412.49
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity439.91296.46332.52179.34201.5575.05
Total Shareholders Equity439.92296.46332.52179.35201.5675.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity439.92296.46332.52179.35201.5675.05
Total Liabilities & Stockholders Equity472.11319.43349.78202.45223.9777.53
Book Value Per Share6.926.016.745.506.1890.62
Tangible Book Value Per Share6.926.016.745.506.1890.62
Full-Time Employees--55---
Price to Book Ratio2.392.082.811.400.110.97
Return on Assets-44.03-65.30-42.67-44.48-33.56-53.12
Return on Equity-47.78-69.77-44.88-50.23-38.06-59.01
Return on Invested Capital-12.66-13.59-9.58-13.98-15.88-3.36
Quick Ratio14.9314.2921.099.0110.3132.01
Current Ratio14.9314.2921.099.0110.3132.01

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-55.77-40.37-31.93-25.18-67.78-2.52
Depreciation0.010.010.010.010.000.00
Other Funds (Non Cash)13.276.948.814.1027.020.96
Funds from Operations-42.48-33.42-23.11-21.06-40.77-1.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.179.34-10.54-1.064.23-0.83
Cash from Operating Activities-43.66-24.08-33.65-22.12-36.53-2.38
Capital Expenditures0.000.00-0.00-0.06-0.140.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-97.63-8.47-98.19-148.59-12.8512.85
Purchase of Investments-142.32-73.90-112.60-148.590.000.00
Sale Or Maturity of Investments44.6965.4314.410.00-12.8512.85
Other Uses0.000.000.03-0.060.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-97.63-8.47-98.16-148.71-12.9912.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock1.530.04170.160.00190.450.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.530.04170.160.00190.450.00
Proceedsfrom Stock Options0.000.00171.410.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow191.99-0.840.000.000.160.00
Other Financing Activities Uses0.00-0.840.000.000.000.00
Cash from Financing Activities193.52-0.80170.160.00190.610.00
Exchange Rate Effect-0.07-0.01-0.02---
Net Change in Cash52.16-33.3538.33-170.84141.0910.47
Free Cash Flow-43.66-24.08-33.65-22.18-36.67-2.38

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.04%10.4M54.5M894.02K
2026-10-1520.57%11.2M54.5M899.85K
2026-09-3022.24%12.1M54.5M901.01K
2026-09-1520.15%11.0M54.5M997.32K
2026-08-3118.48%10.0M54.1M1.11M
2026-08-1417.66%9.7M54.7M1.12M
2026-07-3116.67%8.7M52.1M1.03M
2026-07-1514.44%7.5M52.1M1.04M
2026-06-3016.27%8.1M50.1M997.39K
2026-06-159.88%4.9M50.1M809.56K
2026-05-297.79%3.2M40.6M593.98K
2026-05-158.37%3.4M40.6M544.20K
2026-04-307.49%3.1M41.4M510.25K
2026-04-157.41%3.1M41.3M417.98K
2026-03-313.07%1.3M40.8M336.10K
2026-03-133.77%1.5M40.8M318.65K
2026-02-273.83%1.6M40.8M307.62K
2026-02-134.10%1.6M38.0M314.11K
2026-01-303.80%1.4M38.1M311.64K
2026-01-153.53%1.3M38.1M294.52K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5012.0016.400.0029.1500.000.000.993-0.0180.000
call5.009.5013.800.0012.4620.000.000.942-0.1410.003
call7.507.0011.206.768.3620.000.000.908-0.1410.004
call10.004.508.8013.156.2312.000.000.865-0.1320.006
call12.502.006.400.004.6290.000.000.804-0.1150.007
call15.000.004.901.004.2204620.000.713-0.2840.009
call17.500.004.900.505.21680.0090.000.625-0.2770.010
call20.000.004.905.881.6117.000.000.266-0.0760.009
call22.500.004.902.752.10280.000.000.222-0.0900.008
call25.000.004.900.002.5020.000.000.197-0.1000.007
call30.000.004.902.153.1393.000.000.169-0.1140.007
call35.000.004.900.253.6372.000.000.154-0.1240.006
call40.000.004.900.004.0460.000.000.143-0.1310.006
put2.500.000.050.005.8030.000.00-0.007-0.0160.001
put5.000.004.900.008.2170.000.00-0.058-0.1370.003
put7.500.004.900.005.7350.000.00-0.093-0.1360.004
put10.000.004.900.004.0790.000.00-0.135-0.1270.006
put12.500.001.001.702.8321.000.00-0.193-0.1120.007
put15.000.004.900.005.9960.000.00-0.284-0.2870.009
put17.500.004.902.504.1762.000.00-0.542-0.0890.010
put20.001.105.502.053.1423.000.00-0.399-0.3320.010
put22.503.508.003.403.7212.000.00-0.419-0.3680.010
put25.006.4010.504.904.1951.000.00-0.435-0.3980.010
put30.0011.1015.5010.504.9441.000.00-0.456-0.4440.010
put35.0016.4020.500.005.5280.000.00-0.471-0.4800.010
put40.0021.1025.500.006.0050.000.00-0.482-0.5090.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-28SCHEDULE 13GSEC
2026-10-27SCHEDULE 13GSEC
2026-09-308-KCurrent report2026-09-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-17SCHEDULE 13GSEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-018-KCurrent report2026-06-29SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-263Initial statement of beneficial ownership of securities2026-06-25SEC
2026-06-268-KCurrent report2026-06-25SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-08SEC
2026-06-09SCHEDULE 13D/ASEC
2026-06-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-06-04424B5SEC
2026-06-03424B5SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-15EFFECTEffectiveness filing by commission orderSEC
2026-05-15EFFECTEffectiveness filing by commission orderSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15424B3SEC
2026-05-13CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.43%
Jupiter Topco LLC10.31%
Fairmount Funds Management LLC7.48%
RA CAPITAL MANAGEMENT, L.P.6.03%
Venrock Adviser, LLC5.29%
Bellevue Group AG5.02%
Paradigm Biocapital Advisors LP4.70%
BlackRock, Inc.4.60%
FRANKLIN RESOURCES INC4.59%
STATE STREET CORP3.84%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF2.52%
Franklin Small Cap Value Fund2.32%
Fidelity Growth Company Fund1.87%
Select Health Care Portfolio1.57%
Fidelity Stock Selector Small Cap Fund1.49%
iShares Russell 2000 ETF1.40%
Fidelity Small Cap Growth Fund1.28%
Janus Henderson Global Life Sciences Fund1.18%
Fidelity Advisor Biotechnology Fund1.15%
JPMorgan Small Cap Growth Fund1.11%

OakChart. JBIO. Cached 15 minutes.

Some panels did not load: insider.